Abstract
Tümör nekroz faktörü-alfa(TNF-alfa) ve diğer inflamatuvar sitokinler immun yanıt gelişiminde aktif rol oynarlar.Günümüzde birçok otoimmun hastalığın tedavisinde kullanılan ve temelde anti inflamatuvar etkinliği olan TNF-alfa inhibitörlerinin nadiren ve paradoksal olarak,sistemik inflamatuvar bir hastalık olan sarkoidoz gelişimine neden olduğu bildirilmiştir. Bu yazıda, ankilozan spondilit nedeni ile TNF-alfa inhibitörü (etanersept) tedavisi aldığı sırada sarkoidoz gelişen bir olgunun bildirilmesi amaçlanmıştır.
Keywords
Tümör Nekroz Faktörü-Alfa. Ankilozan Spondilit Etanercep Sarkoidoz Ankylosing Spondylitis Etarnercept Sarcoidosis Tumor Necrosis Factor-Alpha
References
- 1. Kvien TK, Heiberq, Lie E, Kaufman C, Mikkelsen K, Nordvog BY, Rodevand E. A Norvegian DMARD register: prescriptions of DMARDsand biological agent to patients with inflammatory rheumatic diseases. ClinExpRheumatol2005;23:188-94. 2. Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard J‐P, Houvenagel E, et al. Sarcoid‐likegranulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology. 2009;48(8):883–6. 3. Cuchacovich R, Hagan J, Khan T, Richert A, Espinoza LR. Tumor necrosis factor‐alpha (TNF‐α)‐blockade‐induced hepatic sarcoidosis in psoriaticarthritis (PsA): case reportandreview of theliterature. ClinRheumatol. 2011;30(1):133–7. 4.Vigne C.,Tebib, J.-G., Pacheco, Y., &Coury, F. (2013). Sarcoidosis: An underestimated and potentially severe side effect of anti-TNF-alpha t h e r a p y . J o i n t B o n e S p i n e , 8 0 ( 1 ) , 1 0 4 – 1 0 7 . doi:10.1016/j.jbspin.2012.05.001 5. Gerriets V, Bansal P, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. 2020 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 29494032. 6.Braun J, Davis J, Dougados M, Sieper J, Vander Linden S, Van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20. 7.Borekci S, Atahan E, Demir Yilmaz D, et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosisfactor-α treatment.Respiration.2015;90(3):191-198. doi:10.1159/0004346846 8.Wendling D, Nueffer JP. Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis. Joint Bone Spine. 2018 Dec;85(6):769. doi: 10.1016/j.jbspin.2018.05.001. Epub 2018 May 19. PMID: 29787812. 9.Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55. 10. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis Appearing During Anti‐Tumor NecrosisFactor (alpha) Therapy: A New “Class Effect” Paradoxical Phenomenon. Two Case Reports and LiteratureReview. Semin ArthritisRheum. 2010; 39(4): 313‐9. 11. Cleynen I, Vermeire S. Paradoxicalinflammationinducedby anti‐TNF agents in patientswith IBD. Nat Rev GastroenterolHepatol. 2012;9(9):496– 503. 12. Conrad C, DiDomizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockadeinduces a dysregulatedtype I interferon responswithoutautoimmunity in paradoxicalpsoriasis. NatCommun. 2018;9(1):25. 13.Farah RE, Shay MD. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy. 2007;27(10):1446–8. 14.Cole P, Rabasseda X. The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease. DrugsToday (Barc). 2004;40(4):281–324. 15.Louie GH, Chitkara P, Ward MM. Relapse of sarcoidosis upon treatment withetanercept. AnnRheumDis. 2008; 67(6):896–8. 1 6 . M e n g i G , G ö ğ ü ş F. A R a r e A d v e r s e E ff e c t o f A n t i - TumorNecrosisFactor Alpha Therapy: Sarcoidosis. ArchRheumatol. 2017 Feb 12;32(1):67-70. doi: 10.5606/ArchRheumatol.2017.6055. PMID: 30375550; PMCID: PMC6190941.
Abstract
References
- 1. Kvien TK, Heiberq, Lie E, Kaufman C, Mikkelsen K, Nordvog BY, Rodevand E. A Norvegian DMARD register: prescriptions of DMARDsand biological agent to patients with inflammatory rheumatic diseases. ClinExpRheumatol2005;23:188-94. 2. Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard J‐P, Houvenagel E, et al. Sarcoid‐likegranulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology. 2009;48(8):883–6. 3. Cuchacovich R, Hagan J, Khan T, Richert A, Espinoza LR. Tumor necrosis factor‐alpha (TNF‐α)‐blockade‐induced hepatic sarcoidosis in psoriaticarthritis (PsA): case reportandreview of theliterature. ClinRheumatol. 2011;30(1):133–7. 4.Vigne C.,Tebib, J.-G., Pacheco, Y., &Coury, F. (2013). Sarcoidosis: An underestimated and potentially severe side effect of anti-TNF-alpha t h e r a p y . J o i n t B o n e S p i n e , 8 0 ( 1 ) , 1 0 4 – 1 0 7 . doi:10.1016/j.jbspin.2012.05.001 5. Gerriets V, Bansal P, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. 2020 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 29494032. 6.Braun J, Davis J, Dougados M, Sieper J, Vander Linden S, Van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20. 7.Borekci S, Atahan E, Demir Yilmaz D, et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosisfactor-α treatment.Respiration.2015;90(3):191-198. doi:10.1159/0004346846 8.Wendling D, Nueffer JP. Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis. Joint Bone Spine. 2018 Dec;85(6):769. doi: 10.1016/j.jbspin.2018.05.001. Epub 2018 May 19. PMID: 29787812. 9.Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55. 10. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis Appearing During Anti‐Tumor NecrosisFactor (alpha) Therapy: A New “Class Effect” Paradoxical Phenomenon. Two Case Reports and LiteratureReview. Semin ArthritisRheum. 2010; 39(4): 313‐9. 11. Cleynen I, Vermeire S. Paradoxicalinflammationinducedby anti‐TNF agents in patientswith IBD. Nat Rev GastroenterolHepatol. 2012;9(9):496– 503. 12. Conrad C, DiDomizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockadeinduces a dysregulatedtype I interferon responswithoutautoimmunity in paradoxicalpsoriasis. NatCommun. 2018;9(1):25. 13.Farah RE, Shay MD. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy. 2007;27(10):1446–8. 14.Cole P, Rabasseda X. The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease. DrugsToday (Barc). 2004;40(4):281–324. 15.Louie GH, Chitkara P, Ward MM. Relapse of sarcoidosis upon treatment withetanercept. AnnRheumDis. 2008; 67(6):896–8. 1 6 . M e n g i G , G ö ğ ü ş F. A R a r e A d v e r s e E ff e c t o f A n t i - TumorNecrosisFactor Alpha Therapy: Sarcoidosis. ArchRheumatol. 2017 Feb 12;32(1):67-70. doi: 10.5606/ArchRheumatol.2017.6055. PMID: 30375550; PMCID: PMC6190941.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Clinical Sciences |
| Journal Section | Olgu Sunumu |
| Authors | |
| Publication Date | June 28, 2021 |
| Published in Issue | Year 2021 Volume: 1 Issue: 1 |
Bu çalışma CC BY-NC-SA 4.0 kapsamında lisanslanmıştır . Bu lisansın bir kopyasını görüntülemek için http://creativecommons.org/licenses/by-nc-sa/4.0/ adresini ziyaret edin. 
